Administrative Court Error Complicates Infarmed Vaccine Data Transparency

By João L. Carapinha

February 23, 2026

Infarmed vaccine data transparency

Court Clerical Error Threatens Infarmed Vaccine Data Transparency

Infarmed vaccine data transparency hangs in the balance due to a clerical error by the Lisbon Administrative Court’s secretariat, which sent a January 16 dispatch from Judge Ana de Campos to PÁGINA UM’s former lawyer. This misstep interpreted the outlet’s silence on Infarmed’s compliance with a data release order as implicit confirmation, potentially allowing Infarmed to evade full disclosure of COVID-19 vaccine pharmacovigilance data. Despite PÁGINA UM’s prompt reply, the judge may deem the matter moot, extending litigation and highlighting delays in accessing adverse reaction reports from vaccines and Remdesivir.

Gaps in Released Vaccine Data

Partial pharmacovigilance data from Infarmed, released in August 2024 and covering only December 2020 to December 2021, reveals critical omissions like causality grading, dose numbers, batch details, age, municipality, and notifier profession. Of 27,220 adverse reactions, 7,110 were serious, including 104 deaths—such as an 80+ year-old woman dying two minutes after Pfizer vaccination and a man from pulmonary thromboembolism 15 minutes post-dose. Under-25s saw 513 serious reactions (225 without follow-up), plus nine deaths in the 25-49 group. Broader Portal RAM data to August 2024 showed 19,224 of 45,337 entries (42.4%) with “unknown” outcomes, including myocarditis/pericarditis, anaphylaxis, embolisms, Guillain-Barré, strokes, thromboses, and infarctions.

PÁGINA UM’s December 6, 2021, request for Remdesivir and COVID-19 vaccine data was denied by Infarmed under Rui Santos Ivo, leading to the Commission on Access to Administrative Documents. On March 16, 2022, it ordered anonymized release, rejecting refusals. Infarmed’s non-compliance triggered summons, a March 2023 overturned ruling, and a July 11, 2024, Tribunal Central Administrativo do Sul order for full data. Infarmed’s truncated response prompted PÁGINA UM’s July 2024 fine request (€200 minimum daily on Ivo).

Reference url

Recent Posts

Dutch Medicine Access Delay
Dutch Medicine Access Delay Impact on Patient Care in the Netherlands

By João L. Carapinha

June 10, 2026

Dutch Medicine Access Delay leaves patients in the Netherlands waiting far longer for innovative drugs than those in Germany. Of 51 treatments currently held in the Dutch assessment pathway, 48 are already on the market across the border, revealing a persistent structural lag driven by mandatory ...
Factor XIa Inhibition Stroke
Advancements in Factor XIa Inhibition Stroke Prevention Through Asundexian

By HEOR Staff Writer

June 10, 2026

The European Medicines Agency has accepted Bayer’s marketing authorization application for asundexian, marking a major advance in Factor XIa Inhibition Stroke prevention. This oral agent selectively interrupts a key step in the coagulation cascade to reduce recurrent ischemic stroke risk in adult...
clinical skill assessment
Transforming Clinical Skill Assessment with Intelligent Evaluation Systems

By HEOR Staff Writer

June 10, 2026

Clinical skill assessment has long been hampered by subjective judgments and variability among examiners. A novel unified intelligent framework replaces these manual observations with contrastive learning to deliver objective, trace...